{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:00:52Z","timestamp":1793041252678,"version":"4.5.0"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Overview<\/jats:title>\n                    <jats:p>Cannabinoids have gained increasing attention for their therapeutic potential in treating several neurological conditions, including neurodegenerative diseases, chronic pain, and epilepsy. This review aims to assess the current clinical trials investigating cannabinoids, primarily Tetrahydrocannabinol and Cannabidiol, for neurological disorders. This review will aim to highlight the efficacy, safety, and outcome measures used in these trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Clinical trials were identified using\n                      <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>\n                      , focusing on studies that examined the effects of cannabinoids in treating neurological conditions. All trials that fulfilled the following criteria were included: Phase 1\u20134, focused on cannabinoids as primary intervention, and measured relevant outcomes such as pain relief, cognitive function, or spasticity reduction. Data on conditions, interventions, primary and secondary outcomes, and trial phases were extracted and analysed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 47 clinical trials were identified, including different neurological conditions. The most frequently studied conditions were Multiple Sclerosis, Fibromyalgia, and Parkinson\u2019s Disease. Most trials were in Phase 2, with the primary outcome measures focused on pain management, spasticity, and cognitive function. Secondary outcomes included safety and tolerability measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The review highlights the broad therapeutic potential of cannabinoids in neurology, with promising results in symptom management for conditions like Multiple Sclerosis and Fibromyalgia. However, the lack of standardized study protocols, dosing, and outcome measures presents challenges for broader clinical implementation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>clinicatrials.gov<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1521792","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T02:10:11Z","timestamp":1738807811000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Therapeutic potential of cannabinoids in neurological conditions: a systematic review of clinical trials"],"prefix":"10.3389","volume":"16","author":[{"given":"Alqassem Y.","family":"Hakami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad S.","family":"Alshehri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3389\/fpls.2016.00019","article-title":"Cannabis sativa: the plant of the thousand and one molecules","volume":"7","author":"Andre","year":"2016","journal-title":"Front. Plant Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/35003583","article-title":"Cannabinoids control spasticity and tremor in a multiple sclerosis model","volume":"404","author":"Baker","year":"2000","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/geriatrics5010002","article-title":"Cannabinoids in the older person: a literature review","volume":"5","author":"Beedham","year":"2020","journal-title":"Geriatr. (Basel)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s12035-007-8006-8","article-title":"The endocannabinoid system and Alzheimer's disease","volume":"36","author":"Benito","year":"2007","journal-title":"Mol. Neurobiol."},{"key":"B5","first-page":"8","article-title":"Should CBD Be part of my patients' treatment?","volume":"25","author":"Benson","year":"2019","journal-title":"Altern. Ther. Health Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3390\/diagnostics11010074","article-title":"Neuropathic pain and rehabilitation: a systematic review of international guidelines","volume":"11","author":"Bernetti","year":"2021","journal-title":"Diagn. (Basel)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s00702-019-02018-8","article-title":"Evidence for the use of cannabinoids in Parkinson's disease","volume":"126","author":"Buhmann","year":"2019","journal-title":"J. Neural Transm. (Vienna)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/npp.2017.206","article-title":"CB(1) receptor signaling in the brain: extracting specificity from ubiquity","volume":"43","author":"Busquets-Garcia","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"785176","DOI":"10.3389\/fphys.2021.785176","article-title":"Cannabinoid therapeutics in chronic neuropathic pain: from animal research to human treatment","volume":"12","author":"Campos","year":"2021","journal-title":"Front. Physiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.pneurobio.2017.10.007","article-title":"The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: clues for other neuroinflammatory diseases","volume":"160","author":"Chiurchiu","year":"2018","journal-title":"Prog. Neurobiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41582-019-0284-z","article-title":"Cannabinoids and the expanded endocannabinoid system in neurological disorders","volume":"16","author":"Cristino","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/14740338.2021.1842871","article-title":"The safety of medications used to treat peripheral neuropathic pain, Part 2 (opioids, cannabinoids and other drugs): review of double-blind, placebo-controlled, randomized clinical trials","volume":"20","author":"Cumenal","year":"2021","journal-title":"Expert Opin. Drug Saf."},{"key":"B13","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jagp.2020.07.011","article-title":"The role of neuropsychiatric symptoms in research diagnostic criteria for neurodegenerative diseases","volume":"29","author":"Cummings","year":"2021","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.2174\/138161208785740072","article-title":"The endocannabinoid system in Parkinson's disease","volume":"14","author":"Di Filippo","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"B15","doi-asserted-by":"publisher","first-page":"8711","DOI":"10.1074\/jbc.M114.618447","article-title":"Fatty acid-binding proteins (FABPs) are intracellular carriers for \u03949-tetrahydrocannabinol (THC) and cannabidiol (CBD)","volume":"290","author":"Elmes","year":"2015","journal-title":"J. Biol. Chem."},{"key":"B16","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S1474-4422(19)30411-9","article-title":"The global burden of neurological disorders: translating evidence into policy","volume":"19","author":"Feigin","year":"2020","journal-title":"Lancet Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1097\/j.pain.0000000000002268","article-title":"Cannabinoids, the endocannabinoid system, and pain: a review of preclinical studies","volume":"162","author":"Finn","year":"2021","journal-title":"Pain"},{"key":"B18","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1152\/physrev.00045.2019","article-title":"Neuropathic pain: from mechanisms to treatment","volume":"101","author":"Finnerup","year":"2021","journal-title":"Physiol. Rev."},{"key":"B19","doi-asserted-by":"publisher","first-page":"645","DOI":"10.2165\/00023210-200822080-00003","article-title":"Role of cannabinoids in the management of neuropathic pain","volume":"22","author":"Fontelles","year":"2008","journal-title":"CNS drugs"},{"key":"B20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.msard.2017.06.015","article-title":"Sativex in the management of multiple sclerosis-related spasticity: an overview of the last decade of clinical evaluation","volume":"17","author":"Giacoppo","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"B21","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1185\/030079905X41426","article-title":"Post-marketing surveillance: a UK\/European perspective","volume":"21","author":"Gough","year":"2005","journal-title":"Curr. Med. Res. Opin."},{"key":"B22","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/head.14267","article-title":"The endocannabinoid system and related lipids as potential targets for the treatment of migraine-related pain","volume":"62","author":"Greco","year":"2022","journal-title":"Headache"},{"key":"B23","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2174\/187152709789824660","article-title":"The endocannabinoid system and pain","volume":"8","author":"Guindon","year":"","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"B24","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2174\/187152709789824660","article-title":"The endocannabinoid system and pain","volume":"8","author":"Guindon","year":"","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"B25","doi-asserted-by":"publisher","first-page":"8336561","DOI":"10.1155\/2022\/8336561","article-title":"Managing chronic neuropathic pain: recent advances and new challenges","volume":"2022","author":"Hange","year":"2022","journal-title":"Neurol. Res. Int."},{"key":"B26","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/ejn.12431","article-title":"The molecular interplay between endocannabinoid and neurotrophin signals in the nervous system and beyond","volume":"39","author":"Keimpema","year":"2014","journal-title":"Eur. J. Neurosci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"5117","DOI":"10.1007\/s11033-022-07223-5","article-title":"Cannabinoid and endocannabinoid system: a promising therapeutic intervention for multiple sclerosis","volume":"49","author":"Khan","year":"2022","journal-title":"Mol. Biol. Rep."},{"key":"B28","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1042\/EBC20190086","article-title":"The endocannabinoid system","volume":"64","author":"Kilaru","year":"2020","journal-title":"Essays Biochem."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.3390\/molecules28062791","article-title":"An individuality of response to cannabinoids: challenges in safety and efficacy of cannabis products","volume":"28","author":"Kitdumrongthum","year":"2023","journal-title":"Molecules"},{"key":"B30","doi-asserted-by":"publisher","first-page":"6079","DOI":"10.3390\/ijms20236079","article-title":"The interplay between the endocannabinoid system, epilepsy and cannabinoids","volume":"20","author":"Kwan Cheung","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s40263-021-00807-y","article-title":"Highly purified cannabidiol for epilepsy treatment: a systematic review of epileptic conditions beyond Dravet syndrome and lennox-gastaut syndrome","volume":"35","author":"Lattanzi","year":"2021","journal-title":"CNS Drugs"},{"key":"B32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.eplepsyres.2019.03.015","article-title":"Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: expanded access program results","volume":"154","author":"Laux","year":"2019","journal-title":"Epilepsy Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"9472","DOI":"10.3390\/ijms22179472","article-title":"The endocannabinoid system: a potential target for the treatment of various diseases","volume":"22","author":"Lowe","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.bpsc.2020.07.016","article-title":"Review of the endocannabinoid system","volume":"6","author":"Lu","year":"2021","journal-title":"Biol. Psychiatry Cognitive Neurosci. Neuroimaging"},{"key":"B35","first-page":"1242","article-title":"What is the safety profile of cannabis-based medications? Analysis of the post-marketing signals from the FDA adverse event reporting system","volume":"45","author":"Lunghi","year":"2022","journal-title":"Drug Saf."},{"key":"B36","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1097\/j.pain.0000000000000428","article-title":"The endocannabinoid system and neuropathic pain","volume":"157","author":"Maldonado","year":"2016","journal-title":"Pain"},{"key":"B37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1201\/9780429260667-1","article-title":"The pharmacohistory of Cannabis sativa","volume-title":"Cannabinoids as therapeutic agents","author":"Mechoulam","year":"2019"},{"key":"B38","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1001\/jamaneurol.2020.0073","article-title":"Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in Dravet syndrome: a randomized clinical trial","volume":"77","author":"Miller","year":"2020","journal-title":"JAMA Neurol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.phrs.2019.02.029","article-title":"Role of endocannabinoid system in dopamine signalling within the reward circuits affected by chronic pain","volume":"143","author":"Mlost","year":"","journal-title":"Pharmacol. Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.phrs.2019.02.029","article-title":"Role of endocannabinoid system in dopamine signalling within the reward circuits affected by chronic pain","volume":"143","author":"Mlost","year":"","journal-title":"Pharmacol. Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.pain.2007.08.028","article-title":"Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial","volume":"133","author":"Nurmikko","year":"2007","journal-title":"Pain"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.jagp.2021.01.015","article-title":"Cannabinoids for agitation in alzheimer's disease","volume":"29","author":"Outen","year":"2021","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1111\/epi.17000","article-title":"Long-term safety and efficacy of add-on cannabidiol in patients with Lennox-Gastaut syndrome: results of a long-term open-label extension trial","volume":"62","author":"Patel","year":"2021","journal-title":"Epilepsia"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.2174\/138161208785740108","article-title":"The endocannabinoid system in Huntington's disease","volume":"14","author":"Pazos","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"B45","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s40266-021-00882-2","article-title":"Safety and tolerability of natural and synthetic cannabinoids in older adults: a systematic review and meta-analysis of open-label trials and observational studies","volume":"38","author":"Pisani","year":"2021","journal-title":"Drugs Aging"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/dddt.s2352","article-title":"Beyond post-marketing research and MedWatch: long-term studies of drug risks","volume":"1","author":"Resnik","year":"2007","journal-title":"Drug Des. Devel Ther."},{"key":"B47","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.yebeh.2016.11.006","article-title":"Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection","volume":"70","author":"Rosenberg","year":"2017","journal-title":"Epilepsy Behav."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.3390\/life12122042","article-title":"GABAergic neurotransmission in human tissues is modulated by cannabidiol","volume":"12","author":"Ruffolo","year":"2022","journal-title":"Life (Basel)"},{"key":"B49","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.bcp.2019.01.001","article-title":"Systemic administration of serotonin exacerbates abdominal pain and colitis via interaction with the endocannabinoid system","volume":"161","author":"Salaga","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"B50","first-page":"153","article-title":"Patient evaluation: precautions and managing expectations","volume-title":"Cannabis and cannabinoid-based medicines in cancer care: a comprehensive guide to medical management","author":"Schecter","year":""},{"key":"B51","first-page":"191","article-title":"Choosing a product, route of administration, initial dosage, titration, monitoring and management of adverse effects","volume-title":"Cannabis and cannabinoid-based medicines in cancer care: a comprehensive guide to medical management","author":"Schecter","year":""},{"key":"B52","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/ptr.2625","article-title":"Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders","volume":"23","author":"Scuderi","year":"2009","journal-title":"Phytother. Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"128","DOI":"10.2337\/dc09-1029","article-title":"Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor","volume":"33","author":"Selvarajah","year":"2010","journal-title":"Diabetes Care"},{"key":"B54","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2174\/1871527316666170413105421","article-title":"Neurological disorders in medical use of cannabis: an update","volume":"16","author":"Solimini","year":"2017","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"B55","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.neuron.2022.12.022","article-title":"THC and CBD: similarities and differences between siblings","volume":"111","author":"Stella","year":"2023","journal-title":"Neuron"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1111\/epi.17866","article-title":"A systematic literature review on the global epidemiology of Dravet syndrome and Lennox-Gastaut syndrome: prevalence, incidence, diagnosis, and mortality","volume":"65","author":"Sullivan","year":"2024","journal-title":"Epilepsia"},{"key":"B57","doi-asserted-by":"publisher","first-page":"4449","DOI":"10.1007\/s00018-016-2300-4","article-title":"The CB(2) receptor and its role as a regulator of inflammation","volume":"73","author":"Turcotte","year":"2016","journal-title":"Cell Mol. Life Sci."},{"key":"B58","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1586\/ern.11.27","article-title":"Sativex(\u00ae) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data","volume":"11","author":"Vermersch","year":"2011","journal-title":"Expert Rev. Neurother."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1002\/epi4.12956","article-title":"Consensus panel recommendations for the optimization of EPIDIOLEX\u00ae treatment for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex","volume":"9","author":"Wechsler","year":"2024","journal-title":"Epilepsia Open"},{"key":"B60","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/978-3-662-46450-2_7","article-title":"The role of the endocannabinoid system in pain","volume":"227","author":"Woodhams","year":"2015","journal-title":"Pain control."},{"key":"B61","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1177\/1073858414524632","article-title":"Endocannabinoids in synaptic plasticity and neuroprotection","volume":"21","author":"Xu","year":"2015","journal-title":"Neurosci."},{"key":"B62","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2165\/11539000-000000000-00000","article-title":"Role of cannabinoids in multiple sclerosis","volume":"25","author":"Zajicek","year":"2011","journal-title":"CNS Drugs"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1521792\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T02:10:17Z","timestamp":1738807817000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1521792\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":62,"alternative-id":["10.3389\/fphar.2025.1521792"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1521792","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,6]]},"article-number":"1521792"}}